Eckert & Ziegler acquires Vitalea Science

Tuesday, September 11, 2012 11:25 AM

Germany-based Eckert & Ziegler Strahlen- und Medizintechnik, through its Californian subsidiary Eckert & Ziegler Isotope Products (EZIP), has agreed to purchase all stock and assets of Vitalea Science. Vitalea Science is a bioanalytical CRO that provides services to researchers and clinicians in drug development supported by validated Accelerator Mass Spectrometry (AMS) technologies.

This method is used in pre-clinical and clinical studies to explore the behavior of drug candidates in the organism. Due to the AMS device’s ultra-sensitivity it is able to detect C14 tagged molecules in microdose levels. Vitalea also provides AMS services for the characterization and identification of non-medical carbon based compounds.

“Vitalea is a unique company with a very unique capability built around the BioMICADAS device, which is the state-of-the-art in AMS technology,” said Frank Yeager, president & CEO of Eckert & Ziegler Isotope Products.

 “The acquisition helps provide the commercial strength of EZAG to the technical prowess of Vitalea,” said Bob Bethem, president & CEO of Vitalea Science.

Vitalea’s scientists include the original developers of AMS technology for applied bioscience at its location in Davis, Calif., near the University of California Davis campus, a center for research into AMS, PET tracers and other early phase medical studies.

Eckert & Ziegler Isotope Products has been producing instrumentation and calibration standards for over 45 years, manufacturing nuclear imaging reference and calibration standards and producing radioactive components for industrial, scientific and medical applications.

Its holding company, Eckert & Ziegler, is a global isotope technology company that processes radioisotopes and develops, manufactures and sells isotope technology components, medical technology equipment and related products. It employs nearly 600 worldwide and generates annual consolidated revenues in excess of $146 million.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs